Home / Technology & Devices (page 10)

Technology & Devices

Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery

SAN DIEGO & MENLO PARK, Calif.–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and Pacific Biosciences (NASDAQ:PACB) today announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences’ …

Read More »

Clinical Genomics and Quest Diagnostics Extend Collaboration to Provide InSure ONE for Colorectal Cancer Screening

BRIDGEWATER, N.J., and SECAUCUS, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) — Clinical Genomics, a leading innovator of tests for colorectal cancer, and Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced a 5-year extension to their U.S. supply agreement for the InSure® ONE™ fecal immunochemical test …

Read More »

23andMe Granted the First and Only FDA Authorization For Direct-to-Consumer Pharmacogenetic Reports

Mountain View, California – October 31, 2018 – In another first, the U.S. Food and Drug Administration (FDA) granted 23andMe de novo authorization to offer reports on pharmacogenetics, indicating how customers’ genetics may influence the way they metabolize certain medications. This is the first authorization of a direct-to-consumer report on pharmacogenetics, and came …

Read More »

Cerus Receives FDA Breakthrough Device Designation for Pathogen-Reduced Cryoprecipitate

CONCORD, Calif.–(BUSINESS WIRE)–Cerus Corporation (Nasdaq:CERS) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s pathogen-reduced cryoprecipitate product candidate. The basis of the designation is improved treatment of massive hemorrhage, a life-threatening medical condition. “The proposed label indication for pathogen-reduced cryoprecipitate would …

Read More »

Halozyme Licenses New ENHANZE Targets For $25 Million Upfront Payment, Future Milestones And Royalties

SAN DIEGO, Oct. 30, 2018 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of a new undisclosed clinical stage therapeutic target, with an option to select two additional targets within …

Read More »

Study Demonstrates DecisionDx-Melanoma Prognostic Test Accuracy in Patients with Stage II-IIIA Melanoma

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the presentation of data highlighting how the accuracy of the DecisionDx®-Melanoma gene expression profile (GEP) test in patients with Stage II and IIIA melanoma can improve adjuvant clinical trial design …

Read More »

QIAGEN Expands Next-Generation Sequencing Portfolio with Oncology and Immuno-Oncology Panels for Research Using GeneReader NGS System and Other Platforms

Hilden, Germany, and Germantown, Maryland, October 29, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of three innovative Sample to Insight workflows for next-generation sequencing (NGS) research in oncology using QIAGEN’s GeneReader NGS System and other NGS platforms. QIAGEN is introducing the novel NGS workflows …

Read More »

Aptatek Receives FDA Breakthrough Device Designation for a Home-Based Test System that Enables Patients to Monitor Blood levels of Phenylalanine in Real Time

PRINCETON, N.J.–(BUSINESS WIRE)–Aptatek BioSciences, Inc. a pioneer in home-based monitoring of small molecule biomarkers, announced that their PKU test system for real time monitoring of blood phenylalanine levels by phenylketonuria (PKU) patients has received Breakthrough Device designation from the FDA Center for Devices and Radiological Health (CDRH). The Aptatek test …

Read More »

Amgen Invests $66 Million in Oxford Nanopore Technologies

THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen’s equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brought to market a proprietary sequencing technology that uses many nanopores …

Read More »

Exact Sciences Strengthens Pipeline Capabilities With Acquisition of Biomatrica, A Leading Provider of Biological Sample Preservation Technology

MADISON, Wis. and SAN DIEGO, Oct. 18, 2018 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) today announced the acquisition of Biomatrica, a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. Biomatrica’s sample collection tubes, which contain proprietary, sample-stabilizing …

Read More »